Peter Edward Fecci
Associate Professor of Neurosurgery
As the Director of both the Brain Tumor Immunotherapy Program and the Center for Brain and Spine Metastasis at Duke University, I focus our programmatic interests on the design, optimization, and monitoring of immune-based treatment platforms for patients with intracranial tumors, whether primary or metastatic. Within this broad scope, however, my own group looks more specifically at limitations to immunotherapeutic success, with a particular focus on understanding and reversing T cell dysfunction in patients with glioblastoma (GBM) and brain metastases. We employ a systematic approach to categorizing T cell dysfunction (Woroniecka et al, Clin Cancer Res 2018 Aug 15;24(16):3792-3802), and whereas our earlier work addressed concerns for regulatory T cell-induced tolerance, we now heavily study T cell ignorance and exhaustion, as well. Regarding the former, we recently published the novel phenomenon of S1P1-mediated bone marrow T cell sequestration in patients with intracranial tumors (Chongsathidkiet et al, Nat Medicine 2018 Sep;24(9):1459-1468). Regarding the latter, we have likewise recently identified and characterized exhaustion as a significant limitation to T-cell function within GBM (Woroniecka et al, Clin Cancer Res 2018 Sep 1;24(17):4175-4186). I very much look to collaboratively integrate our approaches with others investigating innovative treatment options. I continue my focus on combining strategies for reversing T cell deficits with current and novel immune-based platforms as a means of deriving and improving rational and precise anti-tumor therapies. It is my sincerest desire to forge a career focused on co-operative, multi-disciplinary, organized brain tumor therapy. Ultimately, my goal is to help coordinate the efforts of a streamlined and effective center for brain tumor research and clinical care. I hope to play some role in ushering in a period where the science and treatment arms of brain tumor therapy suffer no disjoint, but instead represent the convergent efforts of researchers, neuro-oncologists, medical oncologists, radiation oncologists, biomedical engineers, and neurosurgeons alike. I hope to see such synergy become standard of care.
Appointments and Affiliations
- Associate Professor of Neurosurgery
- Assistant Research Professor in Immunology
- Associate Professor in Pathology
- Member of the Duke Cancer Institute
- Office Location: 201 Sands Bldg., Box 3050, Durham, NC 27710
- Office Phone: (919) 681-2610
- Email Address: email@example.com
- Massachusetts General Hospital, 2014
- Dana Farber Cancer Institute, 2012
- Massachusetts General Hospital, 2013
- Massachusetts General Hospital, 2008
- Ph.D. Duke University, 2007
- M.D. Duke University School of Medicine, 2007
Brain Tumor Immunotherapy
Cancer-Induced Immune Dysfunction
Awards, Honors, and Distinctions
- Paper of the Year. American Association of Physicists in Medicine. 2017
- Visting Scholar. National Institutes of Health. 2017
- Duke Health Scholars Award. Duke University School of Medicine. 2016
- Prince Mahidol Youth Mentor Award. Prince Mahidol Award Foundation. 2016
- Alpha Omega Alpha. Alpha Omega Alpha Medical Honor Society. 2015
- Resident Advocate Award. Duke University Department of Neurosurgery. 2015
- Sontag Distinguished Scientist Award. Sontag Foundation. 2015
- Matson Award for Best Basic Science Research. New England Neurosurgical Society. 2013
- Preuss Award for Neuro-Oncologic Research. Congress of Neurological Surgeons. 2013
- NIH Loan Repayment Program Award. National Institutes of Health. 2011
- Resident Teaching Award. Tufts University School of Medicine. 2008
- Neurosurgery Award. Duke University Department of Neurosurgery. 2007
- Keynote Speaker. Society for Neuro-Oncology. 2006
- Eugene A. Stead Scholar. Duke University School of Medicine. 2001
- Medical Scientist Training Program Fellowship. National Institutes of Health. 2001
- Cornell-Diamante Scholarship. Cornell University. 1999
- Merrill Presidential Scholar. Cornell University. 1999
- Nanaline H. Duke Scholar. Duke University School of Medicine. 1999
- MOLMED 301B: Research in MOLMED - Oncological Sciences
- NSS 301B: Research in NSS
- PATHOL 793: Research Independent Study
In the News
- A Duke Team Just Found Missing Immune Cells That Could Fight Lethal Brain Tumors (Aug 13, 2018 | Duke Health News)
- Duke neurosurgeon: Many factors in McCain's favor as he undergoes cancer treatment (Jul 20, 2017)
- Fecci, PE; Sampson, JH, The current state of immunotherapy for gliomas: an eye toward the future., J Neurosurg, vol 131 no. 3 (2019), pp. 657-666 [10.3171/2019.5.JNS181762] [abs].
- Lorrey, SJ; Sanchez-Perez, L; Fecci, PE, Rescuing imperfect antigens for immuno-oncology., Nat Biotechnol, vol 37 no. 9 (2019), pp. 1002-1003 [10.1038/s41587-019-0248-2] [abs].
- Choi, KJ; Ackall, FY; Truong, T; Cheng, TZ; Kuchibhatla, M; Zomorodi, AR; Codd, PJ; Fecci, PE; Hachem, RA; Jang, DW, Sinonasal Quality of Life Outcomes After Extended Endonasal Approaches to the Skull Base., Journal of Neurological Surgery Part B: Skull Base, vol 80 no. 4 (2019), pp. 416-423 [10.1055/s-0038-1675592] [abs].
- DeChant, C; Chongsathidkiet, P; Wilkinson, D; Wang, H; Kemeny, H; Polania, JW; Cui, X; Laskowitz, D; Fecci, P, Lymphopenia and Bone Marrow T-cell Sequestration Accompanying Stroke are Mediated by T-cell S1P1 Loss, Journal of Neurosurgery, vol 131 no. 1 (2019) [abs].
- Woroniecka, K; Dechant, C; Rhodin, K; Chongsathidkiet, P; Wilkerson, D; Cui, X; Fecci, P, Targeting Immunostimulatory Pathways in Combination with Checkpoint Blockade Improves Survival in Murine Glioma, Journal of Neurosurgery, vol 131 no. 1 (2019) [abs].